Crinetics Pharmaceuticals (CRNX) Reports In-Line Q4 EPS

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 EPS of ($0.88), in-line with the analyst estimate of ($0.88).

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• BofA expects Apple to top analyst expectations on July 30
• Southern Co. (SO) Declares $0.76 Quarterly Dividend; 3.2% Yield
• MainStreet Bancshares, Inc. (MNSB) Tops Q2 EPS by 5c